Cargando…

Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells

An increasing body of evidence supports the important role of adhesion to bone marrow microenvironment components for survival and drug resistance of multiple myeloma (MM) cells. Previous studies suggested that stimulation of Toll-like receptors by endogenous ligands released during inflammation and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdi, J, Mutis, T, Garssen, J, Redegeld, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674459/ https://www.ncbi.nlm.nih.gov/pubmed/23727662 http://dx.doi.org/10.1038/bcj.2013.17

Ejemplares similares

Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells
por: Abdi, Jahangir, et al.
Publicado: (2013)

Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis
por: Abdi, Jahangir, et al.
Publicado: (2014)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
por: Roche, Kyle C., et al.
Publicado: (2022)

IL-32 is induced by activation of toll-like receptors in multiple myeloma cells
por: Aass, Kristin Roseth, et al.
Publicado: (2023)

Cell Death Triggers Induce MLKL Cleavage in Multiple Myeloma Cells, Which may Promote Cell Death
por: Chen, Jing, et al.
Publicado: (2022)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

A case of bortezomib (Velcade)–induced Stevens-Johnson syndrome confirmed by patch test
por: Choi, Gil-Soon, et al.
Publicado: (2021)

Group-assisted purification (GAP) chemistry for the synthesis of Velcade via asymmetric borylation of N-phosphinylimines
por: Xie, Jian-bo, et al.
Publicado: (2014)

Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
por: Chen, Jing, et al.
Publicado: (2021)

Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells
por: Redlich, Sandra, et al.
Publicado: (2013)

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
por: Leigh, Nicholas D., et al.
Publicado: (2014)

Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3
por: Gibbert, Kathrin, et al.
Publicado: (2014)

Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses
por: Albin, Tyler J., et al.
Publicado: (2019)

Platelets modulate multiple markers of neutrophil function in response to in vitro Toll-like receptor stimulation
por: Hally, Kathryn E., et al.
Publicado: (2019)

Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
por: LIN, LEHANG, et al.
Publicado: (2013)

RNA mediated toll-like receptor stimulation in health and disease
por: Dalpke, Alexander H., et al.
Publicado: (2012)

Platelets regulate leucocyte responses to Toll‐like receptor stimulation
por: Hally, Kathryn E, et al.
Publicado: (2018)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
por: Brown, Sarah, et al.
Publicado: (2016)

Interleukin-7 and Toll-Like Receptor 7 Induce Synergistic B Cell and T Cell Activation
por: Bikker, Angela, et al.
Publicado: (2014)

Stimulation of Toll-Like Receptors profoundly influences the titer of polyreactive antibodies in the circulation
por: Gunti, Sreenivasulu, et al.
Publicado: (2015)

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
por: Xun, Yang, et al.
Publicado: (2021)

Multiple Roles of Toll-Like Receptor 4 in Colorectal Cancer
por: Yesudhas, Dhanusha, et al.
Publicado: (2014)

Impaired toll-like receptor 8 signaling in multiple sclerosis
por: Johnson, Tory P, et al.
Publicado: (2013)

Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome
por: Jialal, Ishwarlal, et al.
Publicado: (2012)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Toll-like receptors and NOD-like receptors in rheumatic diseases
por: McCormack, William J, et al.
Publicado: (2009)

Toll-Like Receptor 2 or Toll-Like Receptor 4 Deficiency Does Not Modify Lupus in MRLlpr Mice
por: Freeley, Simon J., et al.
Publicado: (2013)

Recombinant Fasciola hepatica fatty acid binding protein suppresses toll-like receptor stimulation in response to multiple bacterial ligands
por: Ramos-Benítez, Marcos J., et al.
Publicado: (2017)

Toll-Like Receptors in Atherosclerosis
por: Falck-Hansen, Mika, et al.
Publicado: (2013)

Toll-Like Receptors in Angiogenesis
por: Grote, Karsten, et al.
Publicado: (2011)

Toll-like Receptors and Thrombopoiesis
por: Tang, Xiaoqin, et al.
Publicado: (2023)

Polarized Secretion of APRIL by the Tonsil Epithelium Upon Toll-Like Receptor Stimulation
por: Sturm, Nathalie, et al.
Publicado: (2021)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Toll-Like Receptor 4: A Macrophage Cell Surface Receptor Is Activated by Trimethylamine-N-Oxide
por: Hakhamaneshi, Mohammad Saeed, et al.
Publicado: (2021)

Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages
por: Herrera, Juan Luis, et al.
Publicado: (2009)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
por: Bagratuni, Tina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_frag9ks1chl55gg2npir1micb0